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The Effect of Renin Inhibition on Renal Fibrosis new treatment options. One strategy that received considerable attention is the development of the direct renin inhibitor aliskiren. 9 Aliskiren is the first commercially available renin inhibitor, binding to the active site of renin. Because renin acts as the rate-limiting step in the RAAS cascade, its blockade via aliskiren may cause a more complete inhibition of the RAAS with reduced feedback escape effects compared with ACEis or ARBs. 9 Several clinical trials are investigating the nephroprotective potential of renin inhibition in delaying end-stage renal disease. At present, published clinical trials on renin inhibition are limited to its antihypertensive and antiproteinuric effect in diabetic nephropathy. 10 Aliskiren lowers blood pressure and proteinuria in several animal models, including diabetic transgenic and hypertensive rats. [11] [12] [13] However, the potential benefit of a pharmacological intervention by renin inhibition in chronic progressive fibrotic renal diseases irrespective of its antihypertensive effects has not yet been fully evaluated.
In the present study, we investigated whether late treatment with the renin inhibitor aliskiren has nephroprotective effects in COL4A3 −/− mice. The COL4A3 −/− mice serve as a nonhypertensive animal model of progressive renal fibrosis, [14] [15] [16] [17] [18] similar to the human Alport syndrome (AS). 14, 15 AS is a hereditary nephropathy characterized by progressive renal failure, sensorineural deafness, and typical ocular changes. 19 The disease in mice and humans is caused by mutations in the type IV collagen genes, leading to an abnormal composition of the glomerular basement membrane. Previous studies demonstrated that abnormal composition of the glomerular basement membrane-even with normal blood pressure-leads to secondary events, resulting in extensive matrix deposition, inflammation, and renal fibrosis. [14] [15] [16] 18 These events are known to be a major components of progressive kidney failure in all chronic renal diseases. Important endpoints of the present study with aliskiren included lifespan until death from progressive renal failure of treated vs. untreated mice, proteinuria, renal function, glomerular and tubulointerstitial fibrosis, and profibrotic cytokines.
Methods
Animals. Genotyping of COL4A3 −/− mice (Jackson Lab, Bar Harbor, ME) was carried out by PCR as described before. 14, 15 Treatment protocols for the mice were previously approved by local German authorities and supervised by veterinarians. Mice were bred on a 129/SvJ genetic background in pathogenfree housing conditions with a 12-h dark and light period and unlimited access to food and water at the local animal facility.
Experiments. Systolic arterial blood pressure was measured using a noninvasive pressure cuff system (LE5001; Panlab, Barcelona, Spain). Urine was collected by direct punction of the bladder (after mice were sacrificed) or by spontaneous urination on a sterile surface (in living animals). Ten micro liters of urine was used for microelectrophoresis on a gradient polyacrylamide gel, a semiquantitative technique used to qualify and quantify proteinuria. 15, 16, 18 Gels were stained by Coomassie blue and analyzed by densitometry. Serum urea levels were analyzed on a Hitachi 917 Automatic Analyzer (Hitachi, Boehringer Mannheim, Germany).
According to the recommendation of the manufacturer, medication was given at a dosage of 25-mg aliskiren per kg body weight via subcutaneous osmotic minipumps (4-week pump, Model 2004, ALZET Osmotic Pumps; DURECT, Cupertino, CA). Minipumps filled with normal saline were used as placebo controls. The high concentrations of aliskiren needed in mice limited the duration of medical therapy that could be provided through the minipumps. Therapy was initiated in 6-week-old animals already showing renal damage (proteinuria >1 g/l, starting renal fibrosis) and lasted for 4 weeks. For implantation, animals were anesthetized using 50-100 mg/kg ketamine and 10 mg/kg xylazine intraperitonealy.
Heterozygous COL4A3 breeding pairs were used to generate homozygous animals and wild-type control littermates. The mice were divided into three groups:
1. Untreated, wild-type control littermates (total n = 16; 8 survival; 8 sacrificed at week 9.5). 2. Placebo-treated, homozygous COL4A3 −/− littermates, therapy started at 6 weeks of age, minipumps filled with normal saline in 8 animals (total n = 26; 23 survival; 3 sacrificed at week 9.5). 3. Aliskiren-treated homozygous COL4A3 −/− littermates, therapy started at 6 weeks of age, minipumps filled with aliskiren in all animals (total n = 12; 8 survival; 3 sacrificed at week 9.5, 1 animal died during the operation).
Homozygous COL4A3 −/− mice were randomized to group II and III. The filling of osmotic minipumps with saline or aliskiren was blinded (the person performing the operation did not know if the minipumps contained medication or placebo).
Immunofluorescence of tissue sections and scoring fibrosis.
Three animals per group were sacrificed at week 9.5. For paraffin sections, kidneys were fixed as described previously. 15 Paraffin-embedded sections (5 μm) were dewaxed in xylene, rehydrated in graded alcohol, and blocked with 5% bovine serum albumin in Tris-buffered saline at room temperature. Endogenous peroxidases were blocked by treatment with 3% hydrogen peroxide in phosphate-buffered solution for 10 min. Primary antibodies (rabbit antimouse EHS-laminin, a gift from M. Paulsson, Cologne, Germany) were incubated overnight at 4 °C. For detection, sections were incubated with goat anti-rabbit Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PA), which was used as a secondary antibody. Sections were analyzed on a Zeiss Axiophot microscope (Zeiss, Göttingen, Germany). Stained sections were scored for glomerular and tubulointerstitial deposition of extracellular matrix. Glomerulosclerosis was defined as a loss of >50% of the glomerular lumen due to the accumulation of extracellular matrix. Tubulointerstitial fibrosis was evaluated in a similar matter with two blinded observers grading 8-12 kidney sections of three animals original contributions
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per experimental group into 0, 1+, and 2+ accumulation of extracellular matrix.
Immunoblot. Three kidneys from each group, the wild-type controls, untreated and treated COL4A3 −/− animals, were homogenized in a Tris-buffered saline solution containing a cocktail of protease inhibitors (phenylmethylsulfonyl-fluoride, leupeptin, pepstatin). Twenty-microgram protein aliquots (as shown by BCA protein assay (Pierce, Rockford, IL)) were dissolved in LDS-sample buffer, separated on a 4-12% NuPage Novex Bis-Tris Gel (Invitrogen, Carlsbad, CA), transferred to a polyvinylidene fluoride-membrane and blocked with 5% dry milk powder in Tris-buffered saline with Tween-20. Mouse anti-TGFβ1 (1:2,000; R&D Systems, Minneapolis, MN) and rabbit anti-connective tissue growth factor (CTGF) (1:2,000; Abcam, Cambridge, UK) were incubated overnight. The membrane was then incubated with the secondary antibody conjugated with horseradish peroxidase (Dako, Hamburg, Germany) for 1 h at room temperature. The blots were developed by chemiluminescence using ECL (GE-Healthcare, Freiburg, Germany). Protein expression was analyzed by densitometry using the Kd1-software (Kodak, Rochester, NY).
In situ hybridization. Paraffin-embedded sections (5 μm) of kidneys were dewaxed and rehydrated in decreasing ethanol concentrations according to standard histological protocols. After two washes in phosphate-buffered solution, the sections were partially digested by 6 μg/ml proteinase K (Qiagen, Hilden, Germany) for 30 min. Sections were postfixed by 4% formaldehyde for 5 min before hybridization with a digoxigenin (DIG)-labeled RNA probe that was specific for either transforming growth factor-β (TGFβ) mRNA or CTGF mRNA. Probes for in situ hybridization were labeled with DIG by in vitro transcription in the presence of DIG-UTP using reverse transcription-PCR products of TGFβ and CTGF as templates linked to promoters of SP6 or T7 RNA polymerase by molecular cloning. DIG-labeled probes were hybridized to the sections in a hybridization solution at 42 °C overnight. Subsequently, sections were washed twice in 2xSSC and phosphate-buffered solution. Bound probes were detected with (1:500) rabbit anti-DIG-AP (Roche, Penzberg, Germany) in Tris-buffered saline containing 5% dry milk powder and visualized using the 1:50 diluted AP-substrate NBT/BCIP (Roche) at pH 9.5.
Statistics. Data are presented as the mean ± s.e.m. The data were analyzed by log rank statistic, Kaplan-Meier survival analysis, and two-way analysis of variance. results therapeutic aliskiren drug levels and the lack of renal hypertension in col4a3 −/− mice Application of aliskiren via osmotic minipumps revealed therapeutic drug levels in treated mice 3.5 weeks after initiation of therapy (288 ± 44 ng aliskiren/ml vs. 0 ± 0 in placebo controls at week 9.5). Both aliskiren-and placebo-treated mice with osmotic minipumps did not fit in the restraining container, hindering the measurement of systolic blood pressure. However, blood pressure was measured in untreated (without minipump) COL4A3 −/− mice and wild-type controls. Mean systolic blood pressure was only moderately increased in untreated (without minipump) COL4A3 −/− mice compared with wildtype controls at week 9.5. Student's t-test did not identify significant differences in blood pressure ( Table 1) . No signs of severe hypertension, such as heart hypertrophy, increased septum size, or media sclerosis, were found in any of the treated and untreated COL4A3 −/− mice. Other extrarenal end-organ damage in the COL4A3 −/− mice includes hearing loss, however, the therapeutic effect of aliskiren on the inner ear was not examined.
therapy extends the lifespan of col4a3 −/− mice Lifespan was continuously documented over a 12-month period (Figure 1) . No animals died from infections or adverse effects of therapy. The lifespan of placebo-treated COL4A3 −/− mice (group II) was 66.6 ± 4.9 days. The life expectancy of treated mice (group III) significantly increased by 18% to 78.6 ± 8.2 days (P < 0.01).
therapy delays the onset of uremia and reduces proteinuria
Furthermore, aliskiren therapy reduced proteinuria by 8% from 2.3 g/l in untreated animals to 2.2 g/l at week 7.5 (n = 3; Not done 0 ± 0 ng/ml n = 2 288 ± 44 ng/ml n = 3
The systolic mean arterial blood pressure (mm Hg) of COL4A3 −/− mice is not significantly different from that of healthy controls. Due to the size of the osmotic minipumps, treated mice did not fit in the retaining container for measurement of blood pressure. Treated mice received therapeutic drug levels via osmotic minipumps. original contributions
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data not significant; Figure 2 ) and by 32% from 3.0 to 2.3 g/l at week 9.5 (P < 0.05; Figure 3) . Furthermore, in untreated mice, serum urea started to rise above 50 mg/dl at week 7.5 and to 246 ± 27 mg/dl (n = 6) by week 9.5, followed by death soon after (Figure 3) . In contrast, the deviation of urea was delayed by about 1 week in treated mice. At week 9.5, the urea of treated mice rose to 178 ± 20 mg/dl (n = 3).
therapy reduces fibrosis and abnormal matrix deposition
Healthy controls showed a fine tubular and fine glomerular basement membrane (EHS-laminin, Figure 4 , left). In contrast, placebo-treated COL4A3 −/− mice showed increased amounts of extracellular matrix, leading to the complete loss of glomerular function with severe glomerular and tubulointerstitial fibrosis at week 9.5 (Figure 4, right) . Localized shrinkage of the tubular lumen was also noted, indicating the loss of function of different nephrons. The accumulation of extracellular matrix and fibrotic changes of the glomerulus and the tubulointerstitium were less severe in the therapy group at week 9.5 (Figure 4 , middle). In these animals, a relatively preserved glomerular architecture with less mesangial expansion and no apparent tubulointerstitial fibrosis could be noted, suggesting the preserved function of nephrons. For further analysis, tubulointerstitial fibrosis was evaluated by grading eight different kidney sections of three animals per experimental group (a total of 24 sections) into 1+, 2+, and 3+ accumulation of extracellular matrix by two blinded observers. Healthy controls showed no accumulation of extracellular matrix in any section (matrix score 1.06); untreated COL4A3 −/− original contributions
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mice showed an average matrix score of 2.77 at week 9.5. In contrast, compared with the untreated mice, the matrix score of the treated mice significantly improved by ~10% to 2.54 (P < 0.05). Similarly, >150 glomeruli in three different animals of each group were evaluated for glomerulosclerosis at week 9.5 by two blinded observers. Glomerulosclerosis was scored from one to three, one being 0-33%, two being 34-66%, and three being 67-100% accumulation of glomerular extracellular matrix. One out of 167 (0.6%) glomeruli of healthy controls showed grade 3 sclerosis whereas 230 out of 287 untreated COL4A3 −/− mice (80.1%) exhibited grade 3 sclerosis. In contrast, aliskiren therapy significantly improved the glomerulosclerosis score by ~14% (only 102 out of 162 mice had grade 3 glomerulosclerosis, 62.9%, P < 0.05).
therapy reduces the total renal tgFβ1 and ctgF protein expression (western blot) and decreases tubular tgFβ1 and glomerular ctgF production (in situ hybridization)
We speculated that the nephroprotective effect of aliskiren in the COL4A3 −/− mice was due to the downregulation of the profibrotic cytokines TGFβ and CTGF ( Figure 5) . Compared with placebo-treated COL4A3 −/− mice at week 9.5, therapy resulted in the downregulation of TGFβ1 by nearly 33% and of CTGF by >20% based on in the western blot analysis of whole kidney extracts. Furthermore, in situ hybridization of TGFβ and CTGF identified tubular (and to a lesser extent glomerular) cells as major targets of the antifibrotic effect of aliskiren therapy (Figure 6 ). Therapy reduced TGFβ staining in the tubular and periglomerular space (Figure 6b) as well as CTGF staining in the glomerular space (Figure 6e ) compared with placebo-treated COL4A3 −/− mice. In summary, these data point to the key role of glomerular and tubular TGFβ and CTGF production in glomerular fibrotic diseases as major targets of global antifibrotic nephroprotective therapy. discussion COL4A3 −/− mice with AS serve as a model of progressive renal disease leading to renal fibrosis and end-stage renal failure. [14] [15] [16] [17] [18] All untreated animals showed a similar onset of uremia and proteinuria, resulting in death from end-stage renal failure (as confirmed by autopsy and serum-parameters for kidney function) by 10 weeks of age. These changes allowed observation of the nephroprotective potential of the direct renin inhibitor aliskiren. The drug was given after the onset of proteinuria >1 g/l, mimicking the typical clinical setting of nephroprotective therapy in patients with significant proteinuria preceding renal insufficiency. Measurements of serum drug levels in week 9.5 clearly demonstrated that effective drug levels to inhibit renin were delivered during the whole 4-week period. Due to the side effects of osmotic minipumps, such as skin necrosis, aliskiren could not be delivered before 6 weeks of age and could not be applied for a longer time period. Therefore, the onset and length of therapy in the COL4A3 −/− mice is different to previous studies 16, 18 and hinders direct comparison between different modalities of RAAS-blockade. However, the nephroprotective effect of the therapeutic regimen was clearly demonstrated; lifespan, the most evident end point, was prolonged by 18%.
The antihypertensive effect of aliskiren in our nonhypertensive animal model with Alport disease (Table 1 ) was assumed to be mild and not significantly different from treatment with other antihypertensive drugs affecting the RAAS, such as ACEis, ARBs, and vasopeptidase inhibitors. 16, 18 Therefore, the nephroprotective effect of aliskiren cannot be explained by its antihypertensive effects alone. Previous studies demonstrated a similar therapeutic benefit of ACEis-independent of their hypotensive effect-in stroke-prone spontaneously hypertensive rats. 20 Urinary proteins have been shown to induce progressive interstitial fibrosis and the known antiproteinuric effects of ACEis, ARBs, and vasopeptidase inhibitors have been suggested to be nephroprotective. [21] [22] [23] Our study demonstrated a mild, antiproteinuric effect of aliskiren therapy that may have contributed to renoprotection in this model. The antiproteinuric potential of ACEis, ARBs, and vasopeptidase inhibitors did not correlate well with their potential to delay renal failure in previous studies. 16, 18 Therefore, the nephroprotective effect of aliskiren therapy might be explained by additional nephroprotective mechanisms beyond its antiproteinuric and antihypertensive action.
ACEis have been shown to be effective in preserving renal function in several human renal diseases. [2] [3] [4] [21] [22] [23] ACEis block the conversion of angiotensin I to angiotensin II, a growth factor which activates fibroblasts, leading to the increased synthesis of matrix proteins. 24 Angiotensin II is also a profibrotic cytokine, activating mononuclear cells, increasing proinflammatory mediators 24 and regulating matrix degradation. Some of the downstream effects of angiotensin II are mediated directly via the TGFβ pathway, which has been shown to be important in the pathogenesis of renal fibrosis and inflammatory cell infiltration, such as monocytes in AS. [13] [14] [15] 25, 26 Previous data 
original contributions
The Effect of Renin Inhibition on Renal Fibrosis in adrenalectomized stroke-prone spontaneously hypertensive rats demonstrate that not angiotensin II, but aldosterone, increases profibrotic factors in the kidney. 27 Therefore, aldosterone is thought to be another key player in pathogenesis of renal fibrosis, as addressed by Kaito and co-workers in humans with AS. 28 Large-scale trials in humans with AS and further animal experiments should focus on this topic. Our data show that levels of TGFβ and CTGF are increased in untreated COL4A3 −/− mice ( Figure 6 ). Aliskiren therapy reduced TGFβ and CTGF expression while renal function was preserved. These results emphasize the role of TGFβ and CTGF in the progression of renal fibrosis in the COL4A3 −/− mice. Aliskiren has been shown to reduce RAAS activity in several cell culture studies. For example, preincubation with aliskiren in podocyte cultures exposed to glucose decreased the upregulation of angiotensin II. 29 This effect of the renin inhibitor on the local RAAS may contribute to its nephroprotective effect found in the present study because podocytes are key players in the pathogenesis of AS and several other glomerular diseases. 30 RAAS overactivity perpetuates renal impairment through hemodynamic effects and remodeling. These remodeling consequences include the increased production of connective tissue and extracellular matrix, stimulation of apoptosis and chemoattractant activity, leading to the infiltration of macrophages and other inflammatory cells. 23, 31 Furthermore, angiotensin II plays an important role in the chemotaxis of inflammatory cells, such as macrophages and monocytes, and has additional proinflammatory effects. 23, 31 Interstitial inflammation has been shown to be a major participant in the complex pathogenesis of human AS. 32 Likewise, the kidneys of untreated Alport mice show a profound infiltration of inflammatory cells, such as T-lymphocytes and macrophages, as well as an increased number of activated fibroblasts. 15, 16, 18 These preclinical data suggest that aliskiren may have nephroprotective potential in patients with mild chronic renal disease (such as microalbuminuria) but might also have potential in the treatment of patients with progressed chronic renal disease (such as patients with nephrotic syndrome or the beginnings of renal failure). According to our data, the direct renin inhibitor might have superior effects over pure antihypertensive attributes in regards to the prevention and delay of renal end-organ damage because of its additive, antifibrotic nephroprotective potential. However, these findings require confirmation in controlled clinical studies.
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